Using elranatamab to treat relapsed/refractory multiple myeloma

A Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multiple Myeloma

This study is testing if a new drug called elranatamab can help people with tough-to-treat multiple myeloma feel better and keep their disease from getting worse.

Quick facts

• Phase: PHASE2
• Study type: Interventional
• Enrollment: 32 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Massachusetts General Hospital (other)
• Drugs / interventions: elranatamab
• Locations: 3 sites (Boston, Massachusetts and 2 other locations)
• Trial ID: NCT06138275 on ClinicalTrials.gov

What this trial studies

This open-label phase II study investigates the efficacy of elranatamab in patients with relapsed and refractory multiple myeloma who have previously undergone four or more lines of therapy and received idecabtagene vicleucel. Participants will receive elranatamab for up to six months, with ongoing monitoring until disease progression or initiation of alternative treatments. The drug functions by activating T-cells to target and kill myeloma cells, aiming to reduce the risk of disease worsening. The study will enroll approximately 32 participants.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with relapsed or refractory multiple myeloma who have received multiple prior therapies.

Not a fit: Patients who have not received idecabtagene vicleucel or those with ECOG performance status greater than 1 may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve outcomes for patients with advanced multiple myeloma.

How similar studies have performed: While elranatamab is a novel approach, similar bispecific antibody therapies have shown promise in treating multiple myeloma.

Eligibility criteria

Inclusion Criteria:

* Participant has given voluntary signed written informed consent before performance of any study related procedure that is not part of normal medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to their future medical care.
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
* Male or female participants age ≥ 18 years
* The effects of elranatamab on the developing human fetus are unknown. For this reason and because anti-BCMA bispecific antibodies are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of elranatamab administration.
* Prior diagnosis of MM as defined according to IMWG criteria.
* Measurable disease of multiple myeloma as defined by at least one of the following prior to idecabtagene vicleucel infusion:

  * Serum monoclonal protein ≥ 0.5 g/dL. Patients with IgD disease and lower amounts of monoclonal protein may be permitted to enroll with PI approval
  * ≥ 200 mg of monoclonal protein in the urine on 24 hour electrophoresis
  * Serum free light chain ≥ 100 mg/L (10 mg/dL) and abnormal serum free kappa to serum free kappa light chain ratio (\<0.26 or \>1.65)
* Previously treated relapsed and refractory multiple myeloma following idecabtagene vicleucel as infusion as standard of care who have achieved at least a PR or better per IMWG criteria. Patients will have received idecabtagene per label including after at least 4 prior lines of therapy and relapsed after an immunomodulatory drug (IMiD), a proteasome inhibitor and an Anti-CD38 monoclonal antibody
* left ventricular ejection fraction (LVEF) ≥40% as determined by a multiple gated acquisition scan (MUGA) scan or echocardiogram (ECHO).
* Participants must meet the following organ and marrow function as defined below:

  * Absolute neutrophil count ≥1000/microlitre (mcL). Use of granulocyte-colony stimulating factors is permitted if completed at least 7 days prior to planned start of dosing.
  * Platelet count ≥25,000/mcL. Platelet transfusion support is permitted if completed at least 7 days prior to planned start of dosing.
  * Hemoglobin ≥8 g/dL. Red blood cell transfusion support is permitted if completed at least 7 days prior to planned start of dosing.
  * Calculated creatinine clearance ≥30 mL/min by Cockcroft-Gault equation.
  * Patient has adequate hepatic function, as evidenced by each of the following:

    * Serum total bilirubin \<2 mg/dL; and
    * Serum aspartate transaminase (ALT) and/or aspartate transaminase (AST) values \< 2.5 × the upper limit of normal (ULN) of the institutional laboratory reference range. Patients with elevated bilirubin due to Gilbert's syndrome may be permitted with PI approval (e.g. total bilirubin \<3 mg/dL and normal direct bilirubin).
* Ability to understand and the willingness to sign a written informed consent document. (Providing consents in as many languages as possible is encouraged)

Exclusion Criteria:

* Patients with smoldering MM, plasma cell leukemia, POEMS syndrome, or amyloidosis are excluded from this trial.
* Stem cell transplant within 12 weeks prior to enrollment or active graft-versus-host disease (GVHD).
* Active hepatitis B virus, hepatitis C virus, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), HIV, or any active, uncontrolled bacterial, fungal, or viral infection. Active infections must be resolved at least 14 days prior to enrollment.
* Impaired cardiovascular function or clinically significant cardiovascular diseases, defined as any of the following within 6 months prior to enrollment:

  * Acute myocardial infarction or acute coronary syndromes (eg, unstable angina, coronary artery bypass graft, coronary angioplasty or stenting, symptomatic pericardial effusion);
  * Clinically significant cardiac arrhythmias (eg, uncontrolled atrial fibrillation or uncontrolled paroxysmal supraventricular tachycardia);
  * Thromboembolic or cerebrovascular events (eg, transient ischemic attack, cerebrovascular accident, deep vein thrombosis \[unless associated with a central venous access complication\] or pulmonary embolism);
  * Prolonged QT syndrome (or triplicate average QTcF \>470 msec at screening).
* Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
* Ongoing Grade ≥2 peripheral sensory or motor neuropathy.
* History of Guillain-Barré syndrome (GBS) or GBS variants, or history of any Grade ≥3 peripheral motor polyneuropathy.
* Previous treatment with an anti-BCMA (B-cell maturation antigen) bispecific antibody.
* Pregnant women are excluded from this study because elranatamab is an anti-BCMA bispecific antibody agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with elranatamab, breastfeeding should be discontinued if the mother is treated with elranatamab.

Known or suspected hypersensitivity to the study intervention or any of its excipients.

Participants who are receiving any other investigational agents for this condition (if appropriate only).

Live attenuated vaccine must not be administered within 4 weeks of the first dose of study intervention.

Toxicity from previous anticancer therapy must resolve to baseline levels or to grade ≤1, except for alopecia and peripheral neuropathy.

Other surgical (including major surgery within 14 days prior to enrollment), medical or psychiatric conditions including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).

Where this trial is running

Boston, Massachusetts and 2 other locations

• Massachusetts General Hospital — Boston, Massachusetts, United States (RECRUITING)
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States (RECRUITING)
• Beth-Israel Deaconess Medical Center — Boston, Massachusetts, United States (RECRUITING)

Study contacts

• Principal investigator: Noopur Raje, MD — Massachusetts General Hospital
• Study coordinator: Noopur Raje, MD

Conditions: Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma, relapsed/refractory multiple myeloma